Clinical Trials with Glutamatergic Agents
谷氨酸能药物的临床试验
基本信息
- 批准号:8074010
- 负责人:
- 金额:$ 25.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAgonistAllelesAmino AcidsAnimalsBiological MarkersBiological MarkersBrainBrain imagingCharacteristicsClinicalClinical ResearchClinical TrialsCognitionCognitiveCognitive deficitsCollaborationsCollectionCycloserineD-Amino Acid DehydrogenaseDNADataDatabasesDoseFunctional Magnetic Resonance ImagingGenesGenetic PolymorphismGlutamatergic AgentsGlutamatesGlycineMagnetic Resonance SpectroscopyMeasuresMemoryN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNegative FindingNeurobehavioral ManifestationsNeurosciencesPatientsPenetrationPerfusionPharmacologyPhobic anxiety disorderPlacebosPlasmaPlayProductionRegulationRoleSamplingSchizophreniaSerineSerumSiteSymptomsTemporal LobeTestingTimeToxicologycognitive functiondesignimprovednovel strategiesplacebo controlled studyprogramsresponse
项目摘要
This revised submission of the Clinical Trials Section of the Silvio O. Conte Neuroscience Center for the
study of Glutamate Dysregulation in Schizophrenia has been enhanced by a new collaboration with Dr.
Daniel Javitt. We will extend findings produced during the first five years and will examine
possible explanations for the negative findings of our six month trial with D-cycloserine and the "CONSIST"
trial, a 4 month comparison of glycine and D-cycloserine-- neither found effects on negative symptoms or
cognition. Because neither D-cycloserine nor glycine may adequing Dr. Javitt's IND, we will conduct a
placebo-controlled trial of D-serine a glycine site partial agonist, did not produce siginificant improvement in
negative or cognitive symptoms will be followed-up by a new approach in which D-cycloserine is
administered once-weekly. This design is intended to avoid tolerance to repeated dosing with D-cycloserine;
animal studies and recent studies in patients with phobia indicate that single doses substantially improve
cognitive function, but that tolerance develops after approximately two weeks of daily dosing. We
will conduct a trial of D-serine co-treatment. This study follows from a previous finding by Tsai and
colleagues that the more potent, full agonist D-serine may be effective for positive, negative and cognitive
symptoms without evidence for tolerance with repeated dosing. The recent completion of toxicology studies
will allow us to obtain an IND for study of D-serine within the next year. In collaboration with Dr. Yurgelun-
Todd, we will perform fMRI at baseline and week 8 of the D-serine trial to extend our previous
finding of enhanced temporal lobe activation with D-cycloserine which correlated with improvement of
negative symptoms. We will expand our collection of DNA samples and our extensive database
of phenotypic information from 200 to 500 patients to allow examination of alleles relevant to glutamatergic
regulation in relation to clinical characteristics and response to glutamatergic agents. Study of
polymorphisms of G72 and D-amino acid oxidase as predictors of D-serine response is one example. We
will also further pursue our studies of GCPII by examining two additional polymorphisms in a larger sample.
In collaboration with Dr. Yurgelun-Todd, we will also examine NAA/NAAG concentrations in
prefrental cortex as a potential biological marker of GCPII activity.
这是西尔维奥·O·孔特神经科学中心临床试验部分为
精神分裂症中谷氨酸调节失调的研究通过与Dr。
丹尼尔·贾维特。我们将扩展头五年的调查结果,并将审查
对D-环丝氨酸和“Constant”六个月试验阴性结果的可能解释
试验,对甘氨酸和D-环丝氨酸进行了4个月的比较--对阴性症状或
认知力。因为D-环丝氨酸和甘氨酸都不能满足贾维特博士的IND,我们将进行一项
甘氨酸部位部分激动剂D-丝氨酸的安慰剂对照试验未见显著改善
在阴性或认知症状之后,将采用一种新的方法,其中D-环丝氨酸是
每周给药一次。这种设计旨在避免对D-环丝氨酸重复给药的耐受性;
动物研究和最近对恐惧症患者的研究表明,单次注射可显著改善
认知功能,但这种耐受性在大约两周的每日剂量后形成。我们
将进行D-丝氨酸联合治疗的试验。这项研究源于蔡崇信和他之前的一项研究
同事们认为,更有效、更全面的激动剂D-丝氨酸可能对积极、消极和认知有效
症状无耐受证据,反复服药。最近完成的毒理学研究
将使我们能够在明年内获得D-丝氨酸研究的IND。与尤格伦博士合作-
托德,我们将在D-丝氨酸试验的基线和第8周进行功能磁共振成像,以延长我们之前的
D-环丝氨酸增强颞叶激活与改善
阴性症状。我们将扩大我们的DNA样本收集和广泛的数据库
从200到500名患者收集表型信息,以便检查与谷氨酸能相关的等位基因
调节与临床特征和对谷氨酸能药物的反应有关。的研究
G72和D-氨基酸氧化酶的多态作为D-丝氨酸反应的预测因子就是一个例子。我们
我们还将通过在更大的样本中检测另外两个多态来进一步研究GCPII。
与尤格伦-托德博士合作,我们还将检查NAA/NAAG浓度在
前皮质作为GCPII活性的潜在生物标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH T. COYLE其他文献
Combined Use of Tricyclic Antidepressants and Neuroleptics in the Management of Terminally 111 Children: A Report on Three Cases
- DOI:
10.1016/s0002-7138(09)60569-0 - 发表时间:
1985-07-01 - 期刊:
- 影响因子:
- 作者:
MOHAMMAD MAISAMI;BARBARA H. SOHMER;JOSEPH T. COYLE - 通讯作者:
JOSEPH T. COYLE
Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea
用红藻氨酸损伤纹状体神经元可提供亨廷顿舞蹈病的模型
- DOI:
10.1038/263244a0 - 发表时间:
1976-09-01 - 期刊:
- 影响因子:48.500
- 作者:
JOSEPH T. COYLE;ROBERT SCHWARCZ - 通讯作者:
ROBERT SCHWARCZ
JOSEPH T. COYLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH T. COYLE', 18)}}的其他基金
NMDA hypofunction and episodic memory: An animal model
NMDA 功能减退和情景记忆:动物模型
- 批准号:
8074007 - 财政年份:2010
- 资助金额:
$ 25.33万 - 项目类别:
Biomarkers of NMDA dysfunction and D-serine effects
NMDA 功能障碍和 D-丝氨酸效应的生物标志物
- 批准号:
8074011 - 财政年份:2010
- 资助金额:
$ 25.33万 - 项目类别:
Dopamine and NMDA: role in novelty detection
多巴胺和 NMDA:在新颖性检测中的作用
- 批准号:
8074006 - 财政年份:2010
- 资助金额:
$ 25.33万 - 项目类别:
Dopamine and NMDA: role in novelty detection
多巴胺和 NMDA:在新颖性检测中的作用
- 批准号:
7858385 - 财政年份:2009
- 资助金额:
$ 25.33万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 25.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 25.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 25.33万 - 项目类别: